Background Combining two long-acting bronchodilators with complementary mechanisms of
action may provide treatment benefits to patients with chronic obstructive pulmonary disease …

Currently, chronic obstructive pulmonary disease (COPD) is a global health issue and one of
the leading causes of death in the world. COPD therapy includes pharmacological and non …

Background Long‐acting bronchodilators, comprising long‐acting beta 2‐agonists (LABA)
and long‐acting anti‐muscarinic agents (LAMA, principally tiotropium), are commonly used …

Dyspnea refers to the sensation of breathlessness, shortness of breath, or difficulty breathing
that is commonly observed in patients with respiratory and cardiac disease. In the United …

Activity-related dyspnoea is often the most distressing symptom experienced by patients with
chronic obstructive pulmonary disease (COPD) and can persist despite comprehensive …

Dyspnea is the most prevalent symptom among patients with cardiac and respiratory
diseases. It is an independent predictor of mortality in patients with heart disease, COPD …

Este resumen ejecutivo del Informe de 2017 de la Global Strategy for the Diagnosis,
Management, and Prevention of COPD (GOLD) se basa principalmente en las …

Inhaled bronchodilators (alone or in combination) are the cornerstone of treatment for
symptomatic patients with COPD, either as initial/first-line treatment or for second …

Decreasing the frequency and severity of exacerbations is one of the main goals of
treatment for patients with chronic obstructive pulmonary disease. Several studies have …

Chronic obstructive pulmonary disease (COPD) is a major cause of death and disability
worldwide. Inhaled bronchodilators are the mainstay of COPD pharmacological treatment …